CWA
GALT icon

Capital Wealth Alliance’s Galectin Therapeutics GALT Stock Holding History

Capital Wealth Alliance’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,666
Closed -$4K – 178
2019
Q4 		$4K Buy
+1,666
New +$5.79K ﹤0.01% 260

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Capital Wealth Alliance's GALT Position: Q1 2020 in Review

Capital Wealth Alliance sold out of Galectin Therapeutics (GALT) in Q1 2020, closing a stake of 1,666 shares — an estimated $4K sold.

Capital Wealth Alliance first reported a position in GALT in Q4 2019 and held it in 1 quarter. The position peaked at $4K in Q4 2019. 77 funds tracked by Wall St. Rank hold GALT as of Q1 2020.

  • Capital Wealth Alliance reported no remaining Galectin Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Capital Wealth Alliance sold 1,666 Galectin Therapeutics shares in Q1 2020, an estimated $4K.
  • Capital Wealth Alliance first reported a position in Galectin Therapeutics in Q4 2019 and held it in 1 quarter.
  • Capital Wealth Alliance's Galectin Therapeutics position peaked at $4K in Q4 2019.
  • 77 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2020.

Based on Capital Wealth Alliance's 13F filing for Q1 2020, filed 28 Apr 2020.